Area of research
Molecular Biology · Oncology
Research interest
Research focused on Cancer research and EZH2, with related work in Trastuzumab, Colorectal cancer, Cancer. Notable publications include 'IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2+ breast cancer', 'Hypoxic tumor microenvironment activates GLI2 via HIF-1α and TGF-β2 to promote chemoresistance in colorectal cancer', and 'IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel'.
A systematic benchmark of Nanopore long-read RNA sequencing for transcript-level analysis in human cell lines
Targeting P4HA1 promotes CD8+ T cell progenitor expansion toward immune memory and systemic anti-tumor immunity
IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2+ breast cancer
Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy
Stromal induction of BRD4 phosphorylation Results in Chromatin Remodeling and BET inhibitor Resistance in Colorectal Cancer
Hypoxic tumor microenvironment activates GLI2 via HIF-1α and TGF-β2 to promote chemoresistance in colorectal cancer
KDM6B Counteracts EZH2-Mediated Suppression of <i>IGFBP5</i> to Confer Resistance to PI3K/AKT Inhibitor Treatment in Breast Cancer
Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence
HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer
IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel
EZH2-Mediated Inactivation of IFN-γ-JAK-STAT1 Signaling Is an Effective Therapeutic Target in MYC-Driven Prostate Cancer
PDK1 Signaling Toward PLK1–MYC Activation Confers Oncogenic Transformation, Tumor-Initiating Cell Activation, and Resistance to mTOR-Targeted Therapy